Compugen Ltd financial data

Symbol
CGEN on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
26 Harokmim Street, Building D, Holon, Israel
State of incorporation
Israel
Fiscal year end
December 31
Latest financial report
Q4 2023 - Mar 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Operating Margin -38.8 % +91.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 89.2M shares +3.02%
Common Stock, Shares, Outstanding 89.2M shares +3.02%
Common Stock, Value, Issued 247K USD +2.92%
Weighted Average Number of Shares Outstanding, Basic 87.6M shares +1.25%
Weighted Average Number of Shares Outstanding, Diluted 87.6M shares +1.25%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 33.5M USD +346%
Cost of Revenue 2M USD +106%
Research and Development Expense 34.5M USD +12.5%
General and Administrative Expense 9.73M USD -5.7%
Operating Income (Loss) -13M USD +63.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.78M USD +70.9%
Income Tax Expense (Benefit) 8.97M USD +15366%
Net Income (Loss) Attributable to Parent -18.8M USD +44.3%
Earnings Per Share, Basic -0.21 USD/shares +46.2%
Earnings Per Share, Diluted -0.21 USD/shares +46.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.9M USD +25.6%
Marketable Securities, Current 11.7M USD
Other Assets, Current 226K USD -2.59%
Assets, Current 115M USD +33%
Property, Plant and Equipment, Net 1.22M USD -20.6%
Operating Lease, Right-of-Use Asset 1.33M USD -27.2%
Assets 121M USD +28.8%
Accounts Payable, Current 3.5M USD +97.5%
Employee-related Liabilities, Current 3.13M USD +11.1%
Liabilities, Current 26.3M USD +120%
Operating Lease, Liability, Noncurrent 719K USD -45.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -475M USD -4.12%
Stockholders' Equity Attributable to Parent 65.6M USD -15.6%
Liabilities and Equity 121M USD +28.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -35.9M USD -5.2%
Net Cash Provided by (Used in) Financing Activities 3.08M USD +773%
Net Cash Provided by (Used in) Investing Activities 35.5M USD -4.18%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 89.2M shares +3.02%
Common Stock, Par or Stated Value Per Share 0.01 ILS/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.83M USD -2.51%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14.3M USD +24.8%
Deferred Tax Assets, Valuation Allowance 108M USD +1.06%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.23 pure 0%
Deferred Tax Assets, Gross 108M USD +0.95%
Operating Lease, Liability 1.35M USD -29.8%
Depreciation 476K USD -1.25%
Payments to Acquire Property, Plant, and Equipment 172K USD -63.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -18.8M USD +44.3%
Lessee, Operating Lease, Liability, to be Paid 1.44M USD -31.3%
Property, Plant and Equipment, Gross 6.57M USD -15.3%
Operating Lease, Liability, Current 632K USD +3.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 690K USD +3.14%
Lessee, Operating Lease, Liability, to be Paid, Year One 699K USD -21.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 85K USD -48.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 631K USD +3.61%
Deferred Tax Assets, Operating Loss Carryforwards 92.9M USD +1.29%
Lessee, Operating Lease, Liability, to be Paid, Year Four 115K USD +0.88%
Operating Lease, Payments 800K USD -9.5%
Deferred Tax Assets, Net of Valuation Allowance 307K USD -26%
Share-based Payment Arrangement, Expense 4.33M USD +1.22%